ESTA vs WST
Establishment Labs Holdings Inc. vs West Pharmaceutical Services — AI-powered side-by-side comparison
ESTA
Establishment Labs Holdings Inc.
55
Watch
VS
WST
West Pharmaceutical Services
74
Buy
| Metric | ESTA | WST |
|---|
| AI Score |
55
|
74
|
| Price |
$74.23
|
$351.74
|
| P/E Ratio |
-56.78×
|
44.65×
|
| ROE |
-216.9%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
70.5%
|
36.8%
|
| Debt / Equity |
12.20×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.3%
|
| RSI (14) |
14.9
|
58.0
|
| Beta |
1.087
|
1.138
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ESTA versus WST.
WST leads by 19 points.
WST scores 74/100 (Buy) versus ESTA at 55/100 (Watch).
ESTA Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.9% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 89.9x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.9% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 89.9x prices in significant intangible value — Value
- ROE of only -225.9% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 11.04 adds balance-sheet risk to the value case — Value
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical